Immunotherapy has led to a paradigm shift in the treatment of cancer. Current cancer
immunotherapies are mostly antibody-based, thus possessing advantages in regard to …

Cancer immunotherapy using anti‐programmed death‐ligand 1 (PD‐L1) antibodies has
been used in various clinical applications and achieved certain results. However, such …

T cell immunoglobulin and mucin-containing molecule 3 (Tim-3), expressed in dysfunctional
and exhausted T cells, has been widely acknowledged as a promising immune checkpoint …

Blocking the PD-1/PD-L1 interaction has become an important strategy for tumor therapy,
which has shown outstanding therapeutic effects in clinical settings. However, unsatisfactory …

Tumor cells can evade immune surveillance through overexpressing programmed cell death-
ligand 1 (PD-L1) to interact with programmed cell death-1 (PD-1). Besides, tumor-intrinsic …

The review highlights how protein–protein interactions (PPIs) have determining roles in most
life processes and how interactions between protein partners are involved in various human …

Interactions of membrane-resident proteins are important targets for therapeutic
interventions but most methods to study them are either costly, laborious or fail to reflect the …

A series of novel compounds bearing a cyclopropyl linkage were designed, synthesized,
and evaluated as programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) …

Inside PD-1/PD-L1,2 with their inhibitors - ScienceDirect Skip to main contentSkip to article
Elsevier logo Journals & Books Search RegisterSign in View PDF Download full issue Search …

Next‐generation cancer treatments are expected not only to target cancer cells but also to
simultaneously train immune cells to combat cancer while modulating the immune …